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Acutekidneyinjury(AKI)isacommonprobleminboththeinpatientandoutpatientsettingandoftenresultsfromdrugtoxicities.
Traditional methods of identifying AKI, through measurement of blood urea nitrogen and serum creatinine, are problematic in
that they are slow to detect decreases in glomerular ﬁltration rate (GFR) and are inﬂuenced by a variety of factors that are not
related to GFR changes. The problems inherent in a creatinine-based diagnosis of AKI have impeded the development of proper
therapeutics in AKI and posed problems in evaluating nephrotoxicity of drugs and other chemical exposures. In recent years, a
number of new biomarkers of AKI with more favorable test characteristics than creatinine have been identiﬁed and studied in
a variety of experimental and clinical settings. This review will consider the most well-established biomarkers and appraise the
literature, with particular attention given to the use of biomarkers in identifying toxin-mediated AKI.
1.Introduction
AKI, deﬁned as a rapid decline in GFR, is a common prob-
lem, and the incidence has been increasing signiﬁcantly, par-
ticularly in the hospital setting. Recent estimates have sug-
gested that AKI accounts for 1% of all hospital admissions,
complicates 7% of hospitalizations, and is present in up to
20% of critically ill patients [1]. Despite signiﬁcant advances
in both critical care and nephrology, the mortality rate of
hospitalized patients with AKI has remained relatively un-
changedataround50%overthepastfewdecades [2].A wide
variety of etiologies underlies community-acquired AKI,
while ischemia, sepsis, and toxins (including medications)
are the most common etiologies in hospitalized patients.
Criteria for the diagnosis of AKI rely heavily on measure-
mentsofserumcreatinine,acommonpracticeforestimating
renal function for over sixty years. Creatinine is a 113 Dalton
molecule that is derived from phosphocreatinne, which in
turn is a product of creatine metabolism after creatine’s re-
lease from muscle. Creatinine is freely ﬁltered by the glomer-
ulus and excreted thereafter without signiﬁcant metabolism
or reabsorption by the kidney [3]. These properties have
made serum creatinine level a useful surrogate for kidney
function, and the reciprocal relationship between serum cre-
atinine and GFR has been well described [4]. A variety of
equations (e.g., Cockcroft-Gault, MDRD, and CKD-EPI)
have been developed to estimate GFR from a measured se-
rum creatinine level.
Despite its widespread use, however, serum creatinine
has signiﬁcant limitations as a tool for assessing GFR. First
of all, a variety of nonrenal factors inﬂuence creatinine pro-
ductionratesothatcreatinineproductionisvariablenotonly
fromonepatienttothenext,butalsowithinthesamepatient
placed under diﬀerent conditions. Most notably, age, gender,
muscle mass, diet (particularly protein intake), and nutri-
tionalstatusaremajordeterminantsofcreatinineproduction
[5]. While some equations for eGFR account for some of
these variables (such as age and gender in the MDRD equa-
tion), muscle mass and nutritional considerations are not re-
ﬂected by these equations.
Inadditiontothevariabilityofcreatinineproduction,tu-
bular secretion of creatinine can also vary and cause error
in creatinine-derived estimates of GFR. Under normal con-
ditions, tubular secretion of creatinine accounts for roughly2 Journal of Toxicology
10% of creatinine clearance, but this secretion is inhibited
bycertainmedicationssuchastrimethoprimandcimetidine,
leading to elevations in serum creatinine that do not reﬂect
true decrements in GFR [6]. In addition, because it is meas-
ured as a concentration, serum creatinine is inﬂuenced by its
volume of distribution, which can be signiﬁcantly altered by
volume overload (a condition commonly present in both
acute and chronic renal insuﬃciency) [7].
While the inﬂuence of non-renal factors makes serum
creatinineproblematicforestimatingGFRundernormalcir-
cumstances,avarietyofotherproblemsexistinrelyingonse-
rum creatinine for diagnosing AKI. Most importantly, the
temporal relationship between decreases in GFR and resul-
tant elevations in serum creatinine precludes early recogni-
tion of signiﬁcant GFR loss. It has long been known that
substantial loss of GFR may not manifest with elevations in
serum creatinine for several days [8]. In addition, during
non-steady-state conditions, creatinine-based estimates of
GFR are inaccurate, making assessment of true renal func-
tion diﬃcult. Finally, signiﬁcant impairment in GFR increas-
es the proportion of creatinine clearance that can be ascribed
to tubular secretion, which can result in a substantial overes-
timate of GFR once the true GFR falls below 15mL/min [9].
These myriad problems with creatinine limit both clini-
cal practice and the development of new therapeutics in AKI.
To improve recognition and intervention in AKI, clinicians
need tools that are not inﬂuenced by other clinical param-
eters or patient characteristics and that can identify losses
in GFR soon after they occur. An ideal biomarker of AKI
would be a substance that the kidney releases immediately
in response to injury, and that can be detected in the blood
or urine without signiﬁcant metabolism. This biomarker
would be highly sensitive and speciﬁc for injury to the kid-
ney, whether or not that injury inﬂuences total GFR. Bio-
markers with similar favorable characteristics have been em-
ployed in other areas of clinical practice, such as troponin
measurement in the identiﬁcation of myocardial injury.
A variety of new protein-based biomarkers of kidney
injury have been identiﬁed and may augment the traditional
evaluation of kidney function, which has primarily relied on
measurement of small molecules such as creatinine and urea
[10, 11]. In addition, decades of animal research have explor-
edtheuseofmetabolicproﬁlingforthemonitoringofkidney
function and speciﬁc and sensitive detection of injury [12–
15]. Combinatorial metabolite markers have shown promise
and are attractive due to their superior stability compared to
most proteins and the availability of validated and quanti-
tative assays. However, at this point in the development of
metabolic markers, the aforementioned protein biomarkers
of kidney function are closer to making an impact on clinical
practice than novel metabolite marker strategies.
While there has been signiﬁcant progress in identifying
clinical biomarkers of AKI, the ﬁeld is still developing. This
area of research and development is highly important, as im-
proveddetectionofAKIthroughtheuseofbiomarkersmight
leadtoimprovedpatientcarebyallowingmorecarefulavoid-
ance of nephrotoxins, appropriate modiﬁcation of drug dos-
ing,furtherattentiontoﬂuidstatus,andpossiblytherapeutic
interventions that have thus far failed to show beneﬁt due to
Table 1: Studies of AKI Biomarkers.
Clinical setting Patient
population Biomarker References
cardiac surgery
pediatric
NGAL [16, 17]
IL-18 [18]
NGAL + IL-18 [19]
adults
NGAL [20–24]
IL-18 [25, 26]
NGAL + IL-18 [19]
KIM-1 [27, 28]
urinary CysC [29, 30]
critical care
pediatric
NGAL [31, 32]
IL-18 [33]
KIM-1 [34]
adults NGAL [35–37]
KIM-1 [38]
post-transplant adults KIM-1 [39]
urinary CysC [40]
contrast-induced AKI
pediatric NGAL [41]
adults
NGAL [42, 43]
IL-18 [44]
NGAL + IL-18 [45]
cisplatin-induced AKI
animal
studies
NGAL [46]
KIM-1 [47, 48]
urinary CysC [49]
adults NGAL [50]
L-FABP [51]
late detection through creatinine-based monitoring. Toxin-
mediated AKI might be particularly amenable to biomarker
detection given the direct tubular injury imparted by various
nephrotoxins. The remainder of this review will consider the
most prominent biomarkers currently under investigation,
withparticularattentiontotoxin-mediatedAKI.Table 1 pro-
vides references to the most prominent studies of AKI bio-
markers that will be described below.
2. Overview of Biomarkers in Nontoxic AKI
2.1. Neutrophil Gelatinase-Associated Lipocalin (NGAL).
NGAL,a21kDamemberofthelipocalinsuperfamilyofpro-
teins, is expressed by immune cells, hepatocytes, and renal
tubular epithelial cells [52]. It was ﬁrst identiﬁed as a poten-
tial marker for AKI in 2003 through a transcriptome-wide
search for genes upregulated after renal ischemia [53]. This
potential was tested in a series of animal studies that demon-
strated early postischemic upregulation of NGAL transcrip-
tion and translation, particularly in proximal tubular cells.
In vitro studies with cultured human proximal tubular epi-
thelia conﬁrmed this molecule’s ability to detect injury,
as in vitro injury resulted in marked NGAL upregulation.Journal of Toxicology 3
Currently, NGAL levels are measured using either enzyme-
linked immunosorbent assay (ELISA) or the Architect assay
(Abbott Laboratories).
TheroleofNGALasabiomarkerofhumanAKIhasbeen
established through a variety of studies in the settings of crit-
ical illness and postcardiopulmonary bypass (CPB), with the
earliest reports coming from the pediatric literature. In 2005,
a study of 71 children undergoing CPB was reported. In the
20 patients who developed AKI by creatinine criteria, both
serum and urine NGAL levels rose signiﬁcantly within 2
hours of surgery (mean urine NGAL rose from 1.6ug/L to
147ug/L while serum NGAL rose from 3.2ug/L to 61ug/L).
In contrast, creatinine elevations were not appreciated for at
least 1 day following the surgery. Urinary NGAL at 2 hours
was used to deﬁne a receiver-operating characteristic (ROC)
curve that had an area under the curve (AUC) of 0.998, and,
with a cutoﬀ of 50mcg/L, its sensitivity for AKI was 1.00,
and speciﬁcity was 0.98 [16]. A follow-up study in 2007 ex-
amined 120 children undergoing CPB and showed similarly
excellent sensitivity and speciﬁcity for the diagnosis of AKI
using 2-hour plasma NGAL levels. In addition, the 2-hour
postoperative NGAL levels correlated with duration of AKI
and length of hospital stay, while the 12-hour NGAL level
correlated strongly with mortality [17].
As for adults, a study in 2006 of 81 patients undergoing
cardiacsurgeryfoundthatNGALlevelswerefour-foldhigher
in AKI patients as early as one hour postoperatively when
compared to those without AKI [20]. A similar study of 100
adults undergoing cardiac surgery showed that serum NGAL
was a reliable predictor of AKI and correlated with the dura-
tionandseverityofAKI[21–23].Lastly,astudyof50patients
undergoing CPB established ROC curves for AKI prediction
with AUC’s of 0.80 for plasma NGAL and 0.96 for urinary
NGAL [24].
In the critical care arena, NGAL’s predictive value has
beenstudiedmostextensivelyinchildren.Astudyexamining
urinaryNGALin140mechanicallyventilatedchildrenfound
that NGAL levels increased substantially two days before a
signiﬁcant creatinine rise, and the degree of early NGAL ele-
vation correlated with the severity of the AKI [31]. The rise
in NGAL was six-fold higher than in controls. A subsequent
study of 143 critically ill children showed signiﬁcantly higher
NGAL levels in patients with septic shock compared to those
with the systemic inﬂammatory response syndrome, and
both of these critically ill categories had much higher NGAL
levels than healthy controls. In addition, the degree of serum
NGAL elevation seen during the ﬁrst intensive care unit day
wassigniﬁcantlygreaterinpatientswhodevelopedAKIcom-
pared to those who did not (median serum NGAL was
355ng/mL in children with AKI as opposed to 186ng/mL in
those without) [32].
Asforcriticallyilladults,a2010studyevaluated88inten-
sive care unit (ICU) patients and found that an NGAL level
of ≥155nmol/L predicted AKI with 82% sensitivity and 97%
speciﬁcity [35]. A more recent study of 45 patients admitted
with septic shock has found that urine NGAL level 12 hours
before AKI diagnosis was a good predictor of AKI, with an
area under the receiver-operating characteristic (ROC) curve
of 0.86 [36]. While plasma NGAL in this study did not
perform as well, a contemporaneous study described 301 pa-
tients admitted to an ICU in whom plasma NGAL level was a
good predictor of AKI development within the next 48 hours
(area under ROC curve was 0.78), with good correlation
b e t w e e np e a kN G A Ll e v e l sa n dA K Is e v e r i t y[ 37].
NGAL has also been used in a few other clinical settings.
A recent study has reported the use of NGAL in 119 patients
admitted with acute heart failure, with the observation that
NGAL levels at admission were higher in the 11.8% of pa-
tients who developed cardiorenal syndrome within 2-3 days
of hospitalization. The area under the ROC curve for diag-
nosis of AKI was 0.93, and, using a cutoﬀ of 170ng/L, NGAL
predicted the subsequent development of cardiorenal syn-
drome with 100% sensitivity and 86.7% speciﬁcity [54].
NGAL has also been successfully used to identify AKI in
patients following orthotopic liver transplant (OLT). In a
study of 95 patients undergoing OLT, plasma NGAL had an
area under ROC curve of 0.87, and a composite of APACHE
II score above 13 and plasma NGAL above 258 was a power-
f u lp r e d i c t o ro fs e v e r ep o s t o p e r a t i v eA K I[ 55].
Interestingly, NGAL measurements at the time of hospi-
talorICUadmissionhavebeenshowntobeusefulpredictors
of AKI in hospitalized patients. In a 2008 study, 635 adult
patients admitted to a hospital each had a single urine NGAL
measurement made upon arrival to the emergency depart-
ment,andNGALlevelswereshownnotonlytocorrelatewith
the development of AKI but also predict a composite end-
pointofnephrologyconsultation,dialysis,ICUadmission,or
mortality with an odds ratio of 24.71 [56]. Another study of
31 patients measured urine NGAL levels in trauma patients
at admission, and, with a cutoﬀ of 25ng/mL, urine NGAL
had a sensitivity of 0.91 and speciﬁcity of 0.95 in predicting
AKI [57]. For patients admitted to the ICU, NGAL can be a
powerful predictor of AKI severity, as recently demonstrated
in a study of 632 consecutive patients admitted to an ICU
in whom both plasma and urine NGAL levels measured at
admission were associated with AKI severity, and adding
NGAL to a prediction model for development of AKI signifi-
cantly improved the model’s accuracy [58].
There is some evidence that urinary NGAL can be a use-
ful tool in discerning the cause of AKI as well. In a recent
study, 145 hospitalized patients with AKI have been classiﬁed
into diﬀerent categories based on the clinical cause of their
AKI, and urinary NGAL levels were measured. Urinary
NGAL was able to discriminate between intrinsic and prere-
nal causes with a ROC curve AUC of 0.87. In addition, uri-
nary NGAL levels above 104μg/L indicated intrinsic AKI
(likelihood ratio 5.97) while NGAL levels below 47μg/L
made intrinsic AKI unlikely (likelihood ratio 0.2). Using bi-
omarkers to distinguish the etiology of AKI may be of par-
ticular importance in hospitalized patients with multiple po-
tential causes of AKI (e.g., septic patients on potentially
nephrotoxic antibiotics) [59].
2.2. Interleukin-18 (IL-18). Like NGAL, IL-18 plays a role in
the immune system. IL-18 is a widely expressed proinﬂam-
matory cytokine weighing 18kDa. In addition to its in-
volvement in the immune response, this cytokine has been4 Journal of Toxicology
identiﬁedasamediatorofischemicinjuryintheheart,brain,
and kidney. Animal studies ﬁrst explored the role of IL-18
in ischemic AKI. First, inhibiting IL-18 in mice has been
shown to decrease the severity of ischemic AKI [60]. Further
animal studies demonstrated signiﬁcant increases in IL-18
in whole kidney after experimentally induced AKI, and a
series of additional studies using transgenic models or IL-18
neutralizing antiserum have conﬁrmed IL-18’s key role in
ischemic AKI [61–63]. Studies of isolated mouse proximal
tubules have demonstrated increased IL-18 levels in the set-
ting of hypoxia, and mice with ischemic AKI were found to
have elevated urinary levels of IL-18 [64].
These ﬁndings in animal models have lead to extensive
research on IL-18 as a biomarker of AKI in humans. IL-18
levels are typically measured through ELISA or a speciﬁc as-
say developed for their detection (Architect assay, Abbott
Laboratories). A 2004 study ﬁrst examined this possibility by
measuring urinary IL-18 levels in 72 patients, 22 with AKI
(14 with acute tubular necrosis [ATN], 8 prerenal), 5 with
urinary tract infection, 8 with chronic kidney disease, 4 with
nephroticsyndrome,22withrenaltransplant,and11healthy
controls [65]. Among the nontransplant patients, those with
ATN had signiﬁcantly higher IL-18 levels than all others. In
addition, transplant recipients who developed delayed graft
function had signiﬁcantly higher urine IL-18 levels than
those with prompt graft function.
Subsequent studies examined IL-18 in other clinical situ-
ations. The predictive value of elevated IL-18 levels in criti-
cally ill patients was assessed in a nested case-control study
within the Acute Respiratory Distress Syndrome Network
trial (median urine IL-18 was 104pg/mL at 24 hours in the
AKI group versus 0pg/mL in the group without AKI) [66].
Banked urine samples were assayed for IL-18 levels in 52 pa-
tients with AKI and 86 patients with no AKI. IL-18 was
found to be signiﬁcantly elevated up to 48 hours before the
creatinine-deﬁned occurrence of AKI. In addition, elevated
IL-18 levels were found to be an independent predictor of
death. A more recent study in the critical care setting has
involved 451 patients, 86 of whom developed AKI. Urinary
IL-18 was used to construct a ROC curve, and while the AUC
was only 0.62, it was found that elevated urinary IL-18 was
independently predictive of a composite outcome of death
or acute dialysis within 28 days (with an odds ratio of 1.86)
[67].
ThepredictiveabilityofurinaryIL-18hasalsobeendem-
onstrated in critically ill children in 103 pediatric patients
with renal impairment and 34 controls with normal renal
function, with renal failure patients manifesting a >3 fold in-
creaseinurinaryIL-18[33].Asintheadultpopulation,urine
IL-18 levels rose prior to the rise in creatinine in patients
with AKI, and elevated levels were independently associated
with mortality. Further, the degree of urine IL-18 elevation
predicted the severity of AKI.
Asincriticallyillpatients,AKIisalsocommonafterCPB,
both in children and in adults. Comparing 20 children who
developed AKI after CPB with 35 controls whose renal fun-
ctionremainednormal,itwasfoundthatelevatedIL-18isan
earlypredictorofAKIinthissetting(witha>15-foldincrease
at 4 hours in AKI patients versus non-AKI patients) [18]. In
adults undergoing CPB, the early data on urinary IL-18 are
less clear; one study has demonstrated good predictive value
for urinary IL-18 [25] while a larger study did not [26].
The most recent data on AKI following cardiac surgery
comes from the Translational Research Investigating Bio-
marker Endpoints for Acute Kidney Injury (TRIBE-AKI)
study. The pediatric part of this study measured preoperative
and postoperative urine IL-18 and NGAL as well as plasma
NGAL in 311 children undergoing surgery for congenital
heart disease. 17% of the patients reached the primary out-
come of severe AKI, deﬁned as dialysis requirement or dou-
bling of serum creatinine. The highest quintiles of urine IL-
18 and urine NGAL were strongly associated with AKI risk
(adjusted odds ratios of 6.9 and 4.1). Elevated urinary bio-
markers were associated with longer ICU stay, longer hospi-
talization, and longer mechanical ventilation. The AUC’s for
the urine IL-18 ROC curve and the urine NGAL ROC curve
were 0.72 and 0.71, respectively [19].
The TRIBE-AKI study group also examined these bio-
markers in adults following cardiac surgery. 1219 patients
undergoing cardiac surgery had urine IL-18 and NGAL as
well as plasma NGAL measured prior to surgery and for ﬁve
postoperative days. Multivariate analysis revealed that the
highest quintiles of urine IL-18 and plasma NGAL at six
hours were strongly associated with risk of AKI (adjusted
odds ratios of 6.8 and 5, resp.). Higher biomarker levels were
also associated with longer hospitalization, longer length of
ICU stay, higher risk of dialysis, and death [68].
2.3. Kidney Injury Molecule-1 (KIM-1). KIM-1, a type 1
transmembraneproteinwithanimmunoglobulinandmucin
domain, was ﬁrst described in 1998 [69]. In normal kidney
tissue, it is expressed at a low level, but, following ischemic
injury, it is dramatically upregulated in regenerating proxi-
maltubules.Animalstudieshaveshownthatlevelsofurinary
KIM-1 increase in models of ischemic AKI, sometimes with-
out concomitant blood urea nitrogen or creatinine elevation
[70, 71]. KIM-1 levels are measured using ELISA.
KIM-1’s use as a biomarker of AKI in humans was sug-
gested in a 2002 study that described urinary KIM-1 levels in
patients with AKI. In 7 patients with ischemic acute tubular
necrosis (ATN), mean KIM-1 levels were signiﬁcantly higher
than in 16 patients with other forms of AKI (2.92ng/mL
versus 0.63ng/mL) [72]. This study also described immuno-
histochemical evaluation of six patients with proven ATN; all
tissue samples showed extensive KIM-1 expression in proxi-
mal tubule cells.
A 2009 report described biomarker measurements from
90 adult cardiac surgery patients, 36 of whom developed AKI
[27]. A ROC curve for urinary KIM-1 drawn immediately
after surgery had an AUC of 0.68, which was better than the
value for NGAL. This study also demonstrated that combin-
ing multiple AKI biomarkers improved the overall predictive
value. A more recent study of 123 adults undergoing cardiac
surgery has shown that preoperative KIM-1 levels were able
to predict the development of AKI [28].
Another study published in 2007 described 201 hospi-
talized patients with AKI and demonstrated a correlationJournal of Toxicology 5
between urinary KIM-1 levels and Acute Physiologic and
Chronic Health Evaluation (APACHE) II scores; in addition,
KIM-1 quartiles were shown to correlate with dialysis re-
quirement and hospital mortality [38] .Am o r er e c e n tr e p o r t
in the pediatric literature has described a 252 patient cohort,
7.1% of whom had AKI, in which KIM-1 levels measured in
the emergency department had an area under ROC curve to
predict AKI (pRIFLE criteria I) of 0.73 [34].
A recent study has explored urinary biomarkers in renal
transplant recipients with worsening kidney function. In this
study of 63 transplant recipients biopsied for worsening of
kidney function, the authors reported that the rate of re-
nal function decline over an average of 39.7 months was sig-
nificantly correlated with urinary KIM-1 expression (but not
with NGAL or IL-18). In addition, separating the patients
into low and high KIM-1 groups, graft survival was signif-
icantly worse in the group with high KIM-1 expression [39].
2.4. Cystatin C. Cystatin C, a 13kD protein of the cystatin
family of protease inhibitors, is produced by all nucleated
cells [73]. Serum levels of cystatin C have been established
as a reliable correlate of GFR, superior to serum creatinine in
that cystatin C production is not inﬂuenced by muscle mass;
its level is not aﬀected by age, race, or gender; and its urinary
clearance does not involve tubular secretion. In addition,
serum cystatin C appears to rise 1-2 days earlier than serum
creatinine in the setting of AKI [74]. However, while serum
cystatin C level can be used as a surrogate marker of GFR,
it is not a true biomarker of AKI in that its levels are not a
direct marker of renal injury.
ElevationinurinarycystatinC,ontheotherhand,isclos-
er to a true biomarker of AKI. Cystatin C is freely ﬁltered at
theglomerulusandthennearlycompletelyreabsorbedbythe
proximal tubules. Thus, any process that damages the renal
tubules can impair cystatin C reabsorption, which means
that AKI can manifest with elevated urinary cystatin C levels
[75]. Speciﬁcally, it appears that elevated urinary cystatin C
reﬂects renal tubular dysfunction, as opposed to glomerular
injury [76].
Recent human studies on urinary cystatin C have shown
promise in using this measurement as a biomarker of AKI,
withcystatinClevelsassayedbyELISA.Inthesettingofadult
cardiac surgery, a study of 72 patients (34 with AKI) was
used to construct ROC curves for urinary cystatin C that had
AUC’s of 0.705 for the immediate postoperative timepoint
and 0.704 for the 6 hour postoperative timepoint [29].
Within three days of surgery, the ratio of urinary cystatin C
to urine creatinine ratios had increased >20-fold in patients
withAKI,comparedtoa5-foldincreaseinnon-AKIpatients.
In a study of 444 ICU patients (198 with AKI), urinary
cystatin C had an AUC of 0.70 for the diagnosis of AKI and
was found to be independently associated with sepsis, AKI,
anddeath[30].Astudyof91patientswhoreceiveddeceased-
donor kidney transplants showed that urinary cystatin C
could predict delayed graft function (AUC of 0.74 for the 6
hoururinecystatinC/creatinineratio).Inaddition,theurine
cystatin C/creatinine ratio on the ﬁrst postoperative day was
signiﬁcantly associated with 3-month graft function [40].
3. Overview of Biomarkers in Toxic AKI
As detailed above, biomarkers of AKI have been studied ex-
tensively in the setting of ischemic AKI, both experimentally
and in clinical scenarios in which ischemia is common (e.g.,
sepsis, cardiopulmonary bypass, etc.). In addition, there has
been a considerable amount of research investigating bio-
markersinnephrotoxicAKI.Thisareaisofparticularimpor-
tance not only because toxin-mediated AKI is so common,
but also because it may aid in the evaluation of drug safety in
the future. In this section, we will consider the evidence for
biomarkers in identifying toxin-mediated AKI.
3.1. Biomarkers in Contrast-Mediated AKI. Contrast-induc-
ed nephropathy (CIN), a form of AKI that results from the
intravascular administration of iodinated contrast media for
radiographic procedures, is a prominent cause of hospital-
acquired AKI. CIN is thought to be the result of renal is-
chemia and vasoconstriction induced by hyperosmolar con-
trast media [77], and it manifests with a rise in serum cre-
atinine typically within 2-3 days of contrast administration
[78]. Although the standard deﬁnitions of CIN are based on
a rise in creatinine over a few days, it is likely that the renal
injury from contrast media begins immediately after admin-
istration and that sensitive early biomarkers could detect the
injury sooner.
A study in 2006 examined urine and serum NGAL levels
after percutaneous coronary intervention (PCI) in 35 adults
[42]. None of these patients developed CIN, but signiﬁcant
increases in serum and urinary NGAL levels were found after
PCI (<50% increases in both serum and urine NGAL at 4-
hours postprocedure). A later study in 91 children under-
going cardiac catheterization and angiography found that in
the 12% of patients who developed CIN, plasma and urine
NGAL levels were excellent predictors of AKI within 2
hours of contrast administration (within 2 hours of contrast
administration,urineNGALwas>10-foldhigher,andserum
NGAL was >4-fold higher in the CIN group than the non-
CIN group) [41] .W i t hal e v e lo f1 0 0n g / m Ls e ta sac u t o ﬀ,
urine NGAL at two hours after procedure had a sensitivity,
speciﬁcity, and ROC curve AUC of 73%, 100%, and 0.92,
respectively. Plasma NGAL had similarly impressive test
characteristics—sensitivity 73%, speciﬁcity 100%, and AUC
0.92. A subsequent study of 30 adults undergoing PCI re-
ported that using a cystatin C-based deﬁnition of AKI,a 25%
rise in serum NGAL had a sensitivity of 91.6% in diagnosing
AKI, a speciﬁcity of 83.3%, and a positive predictive value
of 95.6% [79]. A recent meta-analysis of studies involving
NGAL in contrast nephropathy has reported that the AUC-
ROC after contrast administration was 0.894 [43].
IL-18, described above as a powerful biomarker of is-
chemic AKI, has also been studied in the setting of CIN. A
nested case-control study of 157 patients undergoing elective
PCI did not identify signiﬁcant diﬀerences between urine IL-
18 levels in the 9.5% of patients who developed AKI and
those who did not [44]. Conﬂicting results were reported in
another study that included NGAL in its biomarker analysis.
This study of adults undergoing PCI compared 13 patients
who developed CIN with 27 controls. ROC curves were6 Journal of Toxicology
created for urinary IL-18 and NGAL measured at 24 hours,
and the AUC’s were found to be 74.9% and 73.4%, respec-
tively [45]. Additionally, an increase of 25% from baseline in
the biomarker level at 24 hours had an odds ratio for CIN
o f1 0 . 7f o rI L - 1 8a n d5 . 0f o rN G A L .U r i n a r yI L - 1 8w a sa n
earlier predictor of CIN than serum creatinine, and, unlike
creatinine, urinary IL-18 was found to be an independent
predictor of later major cardiac events.
3.2.BiomarkersinCisplatinToxicity. Cisplatinisamajorpart
of various solid tumor chemotherapy regimens, but signiﬁ-
cant nephrotoxicity is a major dose-limiting side-eﬀect in
up to 20% of patients receiving the drug. While most anti-
neoplastic agents that act by crosslinking DNA cause damage
exclusively to rapidly proliferating cells, cisplatin can also
cause considerable damage to the relatively quiescent cells in
the renal proximal tubule. This toxicity appears to be the re-
sult of local cisplatin accumulation within the proximal tu-
bularepithelium,intracellularconversionofthedrugtotoxic
metabolites, and resultant damage through multiple path-
ways [80]. Eﬀorts to prevent the predictable nephrotoxicity
have been hindered by the lag in diagnosing AKI by creat-
inine criteria, so there is great interest in identifying earlier
and more reliable biomarkers of cisplatin-induced AKI.
Animal studies have demonstrated rapid induction of
NGAL in proximal tubule epithelium within three hours of
high-dose cisplatin administration. In addition, NGAL was
readily detectable in the urine within three hours of dosing,
compared to the 96-hour delay in serum creatinine changes
[46]. Two other animal studies have reported that elevated
levels of urinary KIM-1 can identify cisplatin-AKI earlier
than plasma creatinine or blood urea nitrogen [48, 70], and
a recent animal study has reported urinary cystatin C as a
reliable marker of cisplatin-mediated AKI as well [49]. In ad-
dition to these well-established biomarkers, new biomarkers
for cisplatin-mediated AKI have recently been reported (α-
glutathione-S-transferase for proximal tubular injury, μ-glu-
tathione-S-transferase for distal tubular injury, renal papil-
lary antigen-1 for collecting duct injury, and clusterin for
general kidney injury) [81].
There has been a recent report of using NGAL to identify
cisplatin-induced AKI in humans. In this 2010 study, 24 pa-
tients who received cisplatin were studied, comparing 12 pa-
tients with clinically apparent AKI to those with stable serum
creatininelevels.SerumandurineNGALlevelsweremeasur-
ed at 1 and 4 hours after infusion as well as on days 1, 2, 3, 7,
and15afterinfusion.UrineNGALwasfoundtosigniﬁcantly
increase in the AKI group (a 1000% increase at day 1), and
the rise preceded the creatinine-based diagnosis of AKI by
4.5 days. In addition, amongst the AKI patients, higher urine
NGAL levels appeared to predict residual kidney dysfunction
at 15 days [50].
Finally, urinary L-type fatty acid-binding protein (L-
FABP), an emerging biomarker for AKI, was shown to in-
crease within two hours of cisplatin administration, and L-
FABPlevelscorrelatedwithhistologicalinjuryscoreandGFR
earlier and more consistently than BUN measurements [51].
3.3. Other Nephrotoxin-Mediated AKI. Other forms of toxin-
induced AKI have been studied, but there is less data than
there is for contrast-mediated and cisplatin-induced AKI.
Most of the studies involve KIM-1. A rapid assay for detec-
tion for urinary KIM-1 levels is under development, and in,
rats, it was able to identify AKI caused by cadmium and gen-
tamicin [71]. Other animal studies of urinary KIM-1 in
gentamicin-, thioacetamide-, and cyclosporine-related AKI
demonstrated that this assessment is a sensitive, speciﬁc, and
accurate predictor of these drug toxicities [82]. KIM-1 has
alsobeenshowninanimalstobeanearliermarkerforcadmi-
um-induced nephrotoxicity than standard serum creatinine
and urine protein measurements [83]. In addition, KIM-1
hasalsoshowntoincreaseinadose-dependentfashionwhen
ratsareexposedtoavarietyofothernephrotoxins(hexachlo-
ro-1:3-butadiene, potassium dichromate, and cephaloridine
[84].
Other biomarkers have been evaluated in drug toxicities,
but not as extensively as KIM-1. One recent study examin-
ed twelve biomarkers in rats exposed to puromycin amino-
nucleoside (a glomerular toxin), ﬁnding signiﬁcant NGAL
increases after the toxin was administered [85]. Another sep-
arate series of animal experiments using a variety of medica-
tions with nephrotoxic side-eﬀects (gentamicin, puromycin,
vancomycin, cisplatin, doxorubicin, furosemide, tacrolimus,
and lithium carbonate) showed promising results with a
series of biomarkers including urinary levels of clusterin,
cystatin C, total protein, and beta-2 microglobulin [86]. In
humans, a 2009 study reported promising results using uri-
narycystatinCformonitoringtenofovirnephrotoxicity[87].
3.4. Metabolomic Proﬁling in Nephrotoxin-Mediated AKI.
Metabolomicsreferstothestudyofthemetabolitepoolwith-
in a cell, tissue, or bioﬂuid under a particular set of condi-
tions [88] .T h eﬁ e l do fm e t a b o l o m i c su s e sa n a l y t i c a lt e c h -
niques such as nuclear magnetic resonance (NMR) spectro-
scopy and mass spectrometry (MS) to identify and quantify
a sample’s metabolite pool. Not only can quantiﬁed metabo-
lites serve as biomarkers of certain cellular or tissue injuries,
they may also help elucidate mechanisms of injury, particu-
larly in cases of drug toxicity.
Several animal studies have examined metabolomics in
drug-inducedAKI.Forexample,inratstreatedwithcisplatin
for 48 hours, alterations in urinary glucose, amino acids, and
Krebs cycle intermediates were observed, and changes in
these metabolites preceded any changes in serum creatinine
levels [89]. Another recent study in which rats were dosed
with gentamicin, cisplatin, or tobramycin used a metabolo-
micanalysistodemonstratethatincreasesinurinaryconcen-
trations of amino acids and polyamines could be detected
after the ﬁrst dose of a particular nephrotoxin, before any
histopathological changes had occurred [14]. With prolong-
edexposuretothesetoxins,progressiveurinarylossesofami-
no acids with concomitant decreases of amino acid and nu-
cleoside concentrations in kidney tissue were observed. Uri-
nary concentrations of branched amino acids distinguished
neurotoxin-treated samples from vehicle controls with 70%,
93%, and 100% accuracy after 1, 5 and 28 days of treatment,
respectively.Journal of Toxicology 7
3.5. Metabolomics in Calcineurin Inhibitors (CNI)-Induced
Nephrotoxicity. One of the causes of both AKI and chronic
kidney disease in renal transplant recipients is the use of
CNI’s[90],whicharepotentvasoconstrictorsthathavedirect
negativeeﬀectsonthekidney.Unfortunately,CNI-associated
chronic nephrotoxicity increases with duration of exposure
and is often not fully reversible. This particular type of in-
jury has been studied extensively within the ﬁeld of AKI
metabolomics.
A variety of studies have shown that CNI toxicity can
manifest with qualitative changes in urine metabolite pat-
terns that are typical for proximal tubular injury [10, 11, 91].
More recently, a series of studies has been published that
involved the ﬁrst attempts at metabolite quantiﬁcation with
CNI toxicity. These studies have identiﬁed CNI-induced
changes in glomerular ﬁltration, tubular secretion and ab-
sorption, and kidney cell metabolism, culminating in a pro-
posal for a combinatorial metabolite marker for monitoring
CNI-induced AKI [92] .T h i sm o d e li n v o l v e sm a r k e r so f
glomerular ﬁltration (creatinine), reabsorption (glucose),
tubular cell metabolism (citrate, oxoglutarate, and lactate),
tubular secretion and kidney amino acylase activity (hippu-
rate), and oxidative stress (isoprostanes). The combination
panel also included the levels of trimethylamine-N-oxide, a
metabolite that is released and protects against the protein-
precipitating eﬀect of uric acid.
The association between metabolic changes induced by
CNI’s and the metabolites seen in urine has been conﬁrmed
by further proteomics studies in rats [93]. Compared to un-
treated controls, rats treated with CNI’s showed changes in
the expression of certain enzymes that explained several of
the metabolite changes observed in urine. After six days of
CNItreatment,ratsshowedurinemetabolitepatternssimilar
to those reported for agents known to cause oxidative dam-
age, while pattern changes after 28 days were more typical of
agents that cause S3 tubular damage [93, 94]. In addition,
histological results showed evidence of proximal tubular
damage. In aggregate, these studies suggest the following
mechanism causing the characteristic changes in urine met-
abolite patterns: CNI’s cause endothelial dysfunction and
thereby derail mitochondrial oxidation, causing oxygen rad-
ical formation, inhibition of the Krebs cycle, and decline of
energy production. Proximal tubular cells try to compensate
by activating anaerobic glycolysis and importing Krebs cycle
intermediates from urine.
Translation of the proposed combinatorial biomarkers
into the clinical practice still has to be evaluated. However,
there are encouraging reports that some of these metabolic
changes have been seen in transplant patient populations
[95–97]. In addition, there has been a report of a direct
metabolomic evaluation of a particular drug in humans. In
an open label, placebocontrolled, and crossover study, the
time-dependenttoxicodynamiceﬀectsofasingledoseoforal
cyclosporine A (5mg/kg) on the kidney was assessed in thir-
teen healthy individuals [98]. The increase in urinary 15-
F2t-isoprostane concentrations observed 4-hours after the
administration of cyclosporine indicated an increase in oxi-
dative stress. Unbiased metabolome PCA analysis revealed
signiﬁcant changes in urine metabolites typically associated
with negative eﬀects on proximal tubular cells. The major
metabolites that diﬀered between the 4-hour urine samples
after cyclosporine and the placebo were citrate, hippurate,
lactate, TMAO, creatinine, and phenylalanine. Creatinine
concentrations in serum remained unchanged. A decrease in
citrate concentrations in urine kidney transplant patients
had also been reported by others [99]. These results indicate
that analysis of urinary metabolites was a sensitive enough
maker for the detection of the eﬀects of a single cyclosporine
dose already shortly after drug administration. These results
also suggested that previous results in rats may translate into
humans.
4. Conclusions
Serum creatinine was ﬁrst used for the determination of kid-
ney function around 1917 [100]. Nearly, 100 years later, se-
rum creatinine is still the major determinant of kidney func-
tion. The diagnosis of AKI has traditionally relied on serum
creatinine, a lab measurement fraught with problems. Dif-
ﬁculty in identifying AKI quickly and accurately has led to
signiﬁcant problems in patient care, drug development, and
nephrotoxicity monitoring. New biomarkers of AKI have
been studied in a variety of animal studies and clinical set-
tings and show promise for facilitating earlier and more
accurate recognition of AKI. Further research is needed to
understand the performance of these tests in the settings
of other types of renal injury, but as the use of biomarkers
become more widespread and accepted, our ability to iden-
tify nephrotoxic insults and care for patients with impaired
kidney function should improve.
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